기면증 치료 시장 : 전략적 인사이트와 예측(2026-2035년)

The Global Narcolepsy Treatment Landscape Report is set to reach USD 3.10 billion in 2035, growing at a CAGR of 7.9% from USD 1.56 billion in 2026.

Narcolepsy is a chronic neurological sleep disorder characterized by excessive daytime sleepiness, cataplexy, sleep paralysis, hypnagogic hallucinations, and disrupted nighttime sleep. Current treatment primarily focuses on symptom management using wake-promoting agents, sodium oxybate therapies, stimulants, and antidepressants. The treatment landscape is rapidly evolving with the development of orexin receptor agonists and other disease-modifying therapies designed to address the underlying pathophysiology of the disease.

Market Drivers

Increasing Diagnosis of Narcolepsy

Growing awareness among healthcare professionals, improved diagnostic techniques, and expansion of specialized sleep centers are increasing the number of diagnosed patients worldwide. Earlier diagnosis enables timely treatment initiation and supports market growth.

Advancements in Novel Therapies

The emergence of orexin receptor agonists, improved sodium oxybate formulations, and next-generation wake-promoting agents is significantly expanding treatment options. These therapies aim to provide better symptom control, improved patient adherence, and enhanced quality of life.

Rising Healthcare Investment

Healthcare systems are investing more heavily in sleep medicine infrastructure, neurological care, and rare disease management. Government support and favorable orphan drug policies continue encouraging pharmaceutical innovation in narcolepsy treatment.

Growing Patient Awareness

Educational initiatives by sleep medicine organizations and patient advocacy groups are encouraging earlier diagnosis and increasing treatment adherence, further supporting demand for effective therapies.

Market Restraints

Underdiagnosis and Diagnostic Delays

Narcolepsy remains significantly underdiagnosed in many countries because symptoms often overlap with other neurological, psychiatric, or sleep disorders. Long diagnostic delays continue to limit timely treatment.

High Cost of Advanced Therapies

Innovative therapies, particularly recently approved formulations and emerging biologics, may present affordability challenges in healthcare systems with limited reimbursement coverage.

Limited Specialist Availability

Access to sleep specialists and advanced diagnostic facilities remains uneven across developing regions, restricting treatment availability.

Treatment and Technology Insights

The global narcolepsy treatment market can be segmented by drug class, disease type, age group, distribution channel, end user, and geography.

By drug class, the market includes wake-promoting agents, sodium oxybate therapies, stimulants, antidepressants, orexin receptor agonists, and other supportive therapies. Wake-promoting agents and sodium oxybate therapies currently account for a substantial share of treatment because of their proven effectiveness in managing excessive daytime sleepiness and cataplexy. Orexin receptor agonists are expected to become one of the fastest-growing therapeutic classes as they move toward broader commercialization.

By disease type, the market comprises Narcolepsy Type 1 and Narcolepsy Type 2. Narcolepsy Type 1 represents the larger treatment segment because patients often experience both excessive daytime sleepiness and cataplexy, requiring comprehensive therapeutic management.

By age group, treatment includes pediatric patients, adolescents, adults, and elderly patients. Adults account for the largest treatment population, while pediatric treatment is expected to expand as diagnosis improves.

By distribution channel, therapies are supplied through hospital pharmacies, retail pharmacies, specialty pharmacies, and online pharmacies. Specialty pharmacies continue to gain importance for managing advanced therapies and supporting long-term patient adherence.

Technological innovation continues through digital sleep monitoring, telemedicine, wearable sleep assessment devices, artificial intelligence-assisted diagnostics, and precision medicine, improving disease management and long-term patient outcomes.

Market Trends

The narcolepsy treatment landscape continues to evolve rapidly.

Key trends include:

• Expansion of orexin receptor agonist therapies.
• Increasing adoption of extended-release sodium oxybate formulations.
• Growing use of precision medicine in sleep disorders.
• Greater integration of digital health technologies.
• Increasing investment in rare neurological diseases.
• Expansion of telemedicine for long-term patient monitoring.
• Growing focus on disease-modifying therapeutic approaches.

Regional Insights

North America remains the largest narcolepsy treatment market because of advanced sleep medicine infrastructure, strong pharmaceutical innovation, favorable reimbursement policies, and widespread availability of specialist care.

Europe maintains a significant market share through comprehensive healthcare systems, established sleep medicine networks, and increasing adoption of innovative therapies.

Asia-Pacific is expected to register the fastest growth owing to improving healthcare infrastructure, expanding diagnosis rates, increasing healthcare expenditure, and growing awareness across China, Japan, India, South Korea, and Australia.

Latin America and the Middle East & Africa continue to improve treatment access through expanding healthcare investment, specialist training, and greater awareness of sleep disorders.

Competitive Landscape

The global narcolepsy treatment market includes multinational pharmaceutical companies, biotechnology firms, specialty neurology companies, and sleep medicine developers.

Organizations continue investing in orexin receptor agonists, improved sodium oxybate formulations, wake-promoting therapies, precision neurology, and digital health technologies. Strategic collaborations, licensing agreements, acquisitions, and clinical partnerships remain central to accelerating therapeutic innovation and commercialization. Major companies include Jazz Pharmaceuticals plc, Harmony Biosciences Holdings Inc., Takeda Pharmaceutical Company Limited, Avadel Pharmaceuticals plc, Axsome Therapeutics Inc., Alkermes plc, and Centessa Pharmaceuticals plc.

Future Outlook

The future of the narcolepsy treatment market will be shaped by continued advances in orexin biology, personalized medicine, digital health integration, and disease-modifying therapies. As next-generation orexin-targeted treatments progress toward commercialization, the market is expected to transition from symptomatic management toward therapies that more directly address the underlying mechanisms of narcolepsy.

Growing research investment, supportive regulatory pathways, and expanding patient awareness are expected to create substantial opportunities for innovation through 2035.

Conclusion

The Global Narcolepsy Treatment Market is expected to demonstrate sustained growth through 2035, supported by increasing diagnosis rates, expanding therapeutic innovation, and improved understanding of sleep neuroscience. Although diagnostic delays, reimbursement challenges, and limited specialist access remain important barriers, continued advances in orexin-targeted therapies, digital health technologies, and precision medicine are expected to improve patient outcomes while creating attractive opportunities for pharmaceutical companies, biotechnology firms, healthcare providers, and investors.

Key Benefits of this Report

• Comprehensive analysis of the global narcolepsy treatment market and future growth opportunities.
• Detailed evaluation of treatment modalities, therapeutic innovations, and technology trends.
• Competitive assessment of leading companies, strategic initiatives, and product development.
• Insights into regulatory developments, reimbursement trends, and commercialization opportunities.
• Valuable resource for pharmaceutical companies, biotechnology firms, healthcare providers, investors, consultants, and policymakers.

What Businesses Use Our Reports For

Treatment landscape assessment, market forecasting, competitive intelligence, product portfolio planning, commercialization strategy, licensing and partnership evaluation, investment analysis, market access planning, and long-term strategic decision-making.

Report Coverage

• Historical data from 2021 to 2024, Base Year 2025, and Forecast Period 2026 to 2035
• Comprehensive analysis of the global narcolepsy treatment market by drug class, disease type, age group, distribution channel, end user, and geography
• Evaluation of market size, treatment adoption, competitive dynamics, regulatory environment, technology trends, and future growth opportunities
• Assessment of strategic collaborations, clinical innovation, mergers and acquisitions, commercialization strategies, and reimbursement landscape
• Analysis of wake-promoting agents, sodium oxybate therapies, stimulants, antidepressants, orexin receptor agonists, digital health solutions, precision medicine, and future treatment opportunities through 2035.

TABLE OF CONTENTS

1. Executive Summary

• 1.1 Report Scope and Objectives
• 1.2 Key Findings
• 1.3 Treatment Landscape Highlights
• 1.4 Current Standard of Care Overview
• 1.5 Emerging Treatment Trends
• 1.6 Unmet Needs Assessment
• 1.7 Strategic Insights
• 1.8 Future Outlook

2. Disease Overview

• 2.1 Introduction to Narcolepsy
• 2.2 Disease Classification
  • 2.2.1 Narcolepsy Type 1
  • 2.2.2 Narcolepsy Type 2
  • 2.2.3 Secondary Narcolepsy
• 2.3 Disease Pathophysiology
• 2.4 Orexin/Hypocretin Deficiency Mechanism
• 2.5 Epidemiology Overview
• 2.6 Clinical Manifestations
  • 2.6.1 Excessive Daytime Sleepiness
  • 2.6.2 Cataplexy
  • 2.6.3 Sleep Paralysis
  • 2.6.4 Hypnagogic Hallucinations
  • 2.6.5 Fragmented Nighttime Sleep
• 2.7 Disease Burden Assessment
• 2.8 Unmet Medical Needs

3. Treatment Landscape Overview

• 3.1 Evolution of Narcolepsy Treatment
• 3.2 Historical Treatment Milestones
• 3.3 Current Treatment Paradigm
• 3.4 Treatment Algorithm Analysis
• 3.5 Patient Journey and Treatment Flow
• 3.6 Treatment Challenges
• 3.7 Future Treatment Direction

4. Pharmacological Treatment Landscape

• 4.1 Wake-Promoting Agents
  • 4.1.1 Treatment Overview
  • 4.1.2 Clinical Benefits
  • 4.1.3 Safety Profile
  • 4.1.4 Prescribing Trends
  • 4.1.5 Future Outlook
• 4.2 Sodium Oxybate Therapies
  • 4.2.1 Treatment Overview
  • 4.2.2 Clinical Benefits
  • 4.2.3 Safety Profile
  • 4.2.4 Prescribing Trends
  • 4.2.5 Future Outlook
• 4.3 Low-Sodium Oxybate Therapies
  • 4.3.1 Treatment Overview
  • 4.3.2 Clinical Benefits
  • 4.3.3 Safety Profile
  • 4.3.4 Prescribing Trends
  • 4.3.5 Future Outlook
• 4.4 Histamine H3 Receptor Antagonists/Inverse Agonists
  • 4.4.1 Treatment Overview
  • 4.4.2 Clinical Benefits
  • 4.4.3 Safety Profile
  • 4.4.4 Prescribing Trends
  • 4.4.5 Future Outlook
• 4.5 Central Nervous System Stimulants
  • 4.5.1 Treatment Overview
  • 4.5.2 Clinical Benefits
  • 4.5.3 Safety Profile
  • 4.5.4 Prescribing Trends
  • 4.5.5 Future Outlook
• 4.6 Antidepressants for Cataplexy Management
  • 4.6.1 Treatment Overview
  • 4.6.2 Clinical Benefits
  • 4.6.3 Safety Profile
  • 4.6.4 Prescribing Trends
  • 4.6.5 Future Outlook

5. Non-Pharmacological Treatment Landscape

• 5.1 Lifestyle Management Approaches
  • 5.1.1 Scheduled Naps
  • 5.1.2 Sleep Hygiene Interventions
  • 5.1.3 Behavioral Modifications
  • 5.1.4 Future Outlook
• 5.2 Cognitive and Behavioral Interventions
  • 5.2.1 Cognitive Behavioral Therapy
  • 5.2.2 Patient Education Programs
  • 5.2.3 Supportive Care Strategies
  • 5.2.4 Future Outlook
• 5.3 Multidisciplinary Care Models
  • 5.3.1 Sleep Specialist Management
  • 5.3.2 Neurology-Based Care
  • 5.3.3 Integrated Care Approaches
  • 5.3.4 Future Outlook

6. Treatment Landscape by Disease Type

• 6.1 Narcolepsy Type 1
  • 6.1.1 Current Treatment Practices
  • 6.1.2 Treatment Utilization Trends
  • 6.1.3 Future Outlook
• 6.2 Narcolepsy Type 2
  • 6.2.1 Current Treatment Practices
  • 6.2.2 Treatment Utilization Trends
  • 6.2.3 Future Outlook
• 6.3 Pediatric Narcolepsy
  • 6.3.1 Current Treatment Practices
  • 6.3.2 Treatment Utilization Trends
  • 6.3.3 Future Outlook
• 6.4 Adult Narcolepsy
  • 6.4.1 Current Treatment Practices
  • 6.4.2 Treatment Utilization Trends
  • 6.4.3 Future Outlook

7. Treatment Landscape by Symptom Management

• 7.1 Excessive Daytime Sleepiness
  • 7.1.1 Current Treatment Options
  • 7.1.2 Treatment Adoption Trends
  • 7.1.3 Future Outlook
• 7.2 Cataplexy
  • 7.2.1 Current Treatment Options
  • 7.2.2 Treatment Adoption Trends
  • 7.2.3 Future Outlook
• 7.3 Sleep Paralysis
  • 7.3.1 Current Treatment Options
  • 7.3.2 Treatment Adoption Trends
  • 7.3.3 Future Outlook
• 7.4 Hallucinations
  • 7.4.1 Current Treatment Options
  • 7.4.2 Treatment Adoption Trends
  • 7.4.3 Future Outlook
• 7.5 Nighttime Sleep Disturbances
  • 7.5.1 Current Treatment Options
  • 7.5.2 Treatment Adoption Trends
  • 7.5.3 Future Outlook

8. Emerging Treatment Landscape

• 8.1 Orexin Receptor Agonists
  • 8.1.1 Clinical Development Status
  • 8.1.2 Mechanism of Action
  • 8.1.3 Competitive Assessment
  • 8.1.4 Future Outlook
• 8.2 Novel Wake-Promoting Agents
  • 8.2.1 Clinical Development Status
  • 8.2.2 Mechanism of Action
  • 8.2.3 Competitive Assessment
  • 8.2.4 Future Outlook
• 8.3 Immunomodulatory Therapies
  • 8.3.1 Clinical Development Status
  • 8.3.2 Mechanism of Action
  • 8.3.3 Competitive Assessment
  • 8.3.4 Future Outlook
• 8.4 Gene and Cell-Based Therapies
  • 8.4.1 Clinical Development Status
  • 8.4.2 Mechanism of Action
  • 8.4.3 Competitive Assessment
  • 8.4.4 Future Outlook

9. Treatment Guidelines and Clinical Practice

• 9.1 International Treatment Guidelines
• 9.2 American Academy of Sleep Medicine Recommendations
• 9.3 European Treatment Recommendations
• 9.4 Japanese Treatment Recommendations
• 9.5 Treatment Sequencing Strategies
• 9.6 Physician Prescribing Patterns
• 9.7 Future Guideline Evolution

10. Geographical Analysis

• 10.1 North America
  • 10.1.1 Treatment Utilization Trends
  • 10.1.2 Standard of Care Assessment
  • 10.1.3 Access to Treatment
  • 10.1.4 Reimbursement Environment
  • 10.1.5 Key Market Drivers
  • 10.1.6 Growth Opportunities
• 10.2 Europe
  • 10.2.1 Treatment Utilization Trends
  • 10.2.2 Standard of Care Assessment
  • 10.2.3 Access to Treatment
  • 10.2.4 Reimbursement Environment
  • 10.2.5 Key Market Drivers
  • 10.2.6 Growth Opportunities
• 10.3 Asia-Pacific
  • 10.3.1 Treatment Utilization Trends
  • 10.3.2 Standard of Care Assessment
  • 10.3.3 Access to Treatment
  • 10.3.4 Reimbursement Environment
  • 10.3.5 Key Market Drivers
  • 10.3.6 Growth Opportunities
• 10.4 Latin America
  • 10.4.1 Treatment Utilization Trends
  • 10.4.2 Standard of Care Assessment
  • 10.4.3 Access to Treatment
  • 10.4.4 Reimbursement Environment
  • 10.4.5 Key Market Drivers
  • 10.4.6 Growth Opportunities
• 10.5 Middle East & Africa
  • 10.5.1 Treatment Utilization Trends
  • 10.5.2 Standard of Care Assessment
  • 10.5.3 Access to Treatment
  • 10.5.4 Reimbursement Environment
  • 10.5.5 Key Market Drivers
  • 10.5.6 Growth Opportunities

11. Key Countries Analysis

• 11.1 United States
  • 11.1.1 Treatment Utilization Trends
  • 11.1.2 Prescribing Patterns
  • 11.1.3 Access to Treatment
  • 11.1.4 Reimbursement Environment
  • 11.1.5 Key Market Drivers
  • 11.1.6 Growth Opportunities
• 11.2 Canada
  • 11.2.1 Treatment Utilization Trends
  • 11.2.2 Prescribing Patterns
  • 11.2.3 Access to Treatment
  • 11.2.4 Reimbursement Environment
  • 11.2.5 Key Market Drivers
  • 11.2.6 Growth Opportunities
• 11.3 Germany
  • 11.3.1 Treatment Utilization Trends
  • 11.3.2 Prescribing Patterns
  • 11.3.3 Access to Treatment
  • 11.3.4 Reimbursement Environment
  • 11.3.5 Key Market Drivers
  • 11.3.6 Growth Opportunities
• 11.4 United Kingdom
  • 11.4.1 Treatment Utilization Trends
  • 11.4.2 Prescribing Patterns
  • 11.4.3 Access to Treatment
  • 11.4.4 Reimbursement Environment
  • 11.4.5 Key Market Drivers
  • 11.4.6 Growth Opportunities
• 11.5 France
  • 11.5.1 Treatment Utilization Trends
  • 11.5.2 Prescribing Patterns
  • 11.5.3 Access to Treatment
  • 11.5.4 Reimbursement Environment
  • 11.5.5 Key Market Drivers
  • 11.5.6 Growth Opportunities
• 11.6 Italy
  • 11.6.1 Treatment Utilization Trends
  • 11.6.2 Prescribing Patterns
  • 11.6.3 Access to Treatment
  • 11.6.4 Reimbursement Environment
  • 11.6.5 Key Market Drivers
  • 11.6.6 Growth Opportunities
• 11.7 Spain
  • 11.7.1 Treatment Utilization Trends
  • 11.7.2 Prescribing Patterns
  • 11.7.3 Access to Treatment
  • 11.7.4 Reimbursement Environment
  • 11.7.5 Key Market Drivers
  • 11.7.6 Growth Opportunities
• 11.8 China
  • 11.8.1 Treatment Utilization Trends
  • 11.8.2 Prescribing Patterns
  • 11.8.3 Access to Treatment
  • 11.8.4 Reimbursement Environment
  • 11.8.5 Key Market Drivers
  • 11.8.6 Growth Opportunities
• 11.9 Japan
  • 11.9.1 Treatment Utilization Trends
  • 11.9.2 Prescribing Patterns
  • 11.9.3 Access to Treatment
  • 11.9.4 Reimbursement Environment
  • 11.9.5 Key Market Drivers
  • 11.9.6 Growth Opportunities
• 11.10 India
  • 11.10.1 Treatment Utilization Trends
  • 11.10.2 Prescribing Patterns
  • 11.10.3 Access to Treatment
  • 11.10.4 Reimbursement Environment
  • 11.10.5 Key Market Drivers
  • 11.10.6 Growth Opportunities
• 11.11 South Korea
  • 11.11.1 Treatment Utilization Trends
  • 11.11.2 Prescribing Patterns
  • 11.11.3 Access to Treatment
  • 11.11.4 Reimbursement Environment
  • 11.11.5 Key Market Drivers
  • 11.11.6 Growth Opportunities
• 11.12 Australia
  • 11.12.1 Treatment Utilization Trends
  • 11.12.2 Prescribing Patterns
  • 11.12.3 Access to Treatment
  • 11.12.4 Reimbursement Environment
  • 11.12.5 Key Market Drivers
  • 11.12.6 Growth Opportunities

12. Company Profiles

• 12.1 Jazz Pharmaceuticals plc
  • 12.1.1 Overview
  • 12.1.2 Financials
  • 12.1.3 Narcolepsy Treatment Portfolio
  • 12.1.4 Commercial Strategy
  • 12.1.5 Key Products
  • 12.1.6 Market Position
  • 12.1.7 Strategic Collaborations
  • 12.1.8 Recent Developments
• 12.2 Harmony Biosciences Holdings, Inc.
  • 12.2.1 Overview
  • 12.2.2 Financials
  • 12.2.3 Narcolepsy Treatment Portfolio
  • 12.2.4 Commercial Strategy
  • 12.2.5 Key Products
  • 12.2.6 Market Position
  • 12.2.7 Strategic Collaborations
  • 12.2.8 Recent Developments
• 12.3 Avadel Pharmaceuticals plc
  • 12.3.1 Overview
  • 12.3.2 Financials
  • 12.3.3 Narcolepsy Treatment Portfolio
  • 12.3.4 Commercial Strategy
  • 12.3.5 Key Products
  • 12.3.6 Market Position
  • 12.3.7 Strategic Collaborations
  • 12.3.8 Recent Developments
• 12.4 Takeda Pharmaceutical Company Limited
  • 12.4.1 Overview
  • 12.4.2 Financials
  • 12.4.3 Narcolepsy Treatment Portfolio
  • 12.4.4 Commercial Strategy
  • 12.4.5 Key Products
  • 12.4.6 Market Position
  • 12.4.7 Strategic Collaborations
  • 12.4.8 Recent Developments
• 12.5 Axsome Therapeutics, Inc.
  • 12.5.1 Overview
  • 12.5.2 Financials
  • 12.5.3 Narcolepsy Treatment Portfolio
  • 12.5.4 Commercial Strategy
  • 12.5.5 Key Products
  • 12.5.6 Market Position
  • 12.5.7 Strategic Collaborations
  • 12.5.8 Recent Developments
• 12.6 Centessa Pharmaceuticals plc
  • 12.6.1 Overview
  • 12.6.2 Financials
  • 12.6.3 Narcolepsy Treatment Portfolio
  • 12.6.4 Commercial Strategy
  • 12.6.5 Key Products
  • 12.6.6 Market Position
  • 12.6.7 Strategic Collaborations
  • 12.6.8 Recent Developments
• 12.7 Alkermes plc
  • 12.7.1 Overview
  • 12.7.2 Financials
  • 12.7.3 Narcolepsy Treatment Portfolio
  • 12.7.4 Commercial Strategy
  • 12.7.5 Key Products
  • 12.7.6 Market Position
  • 12.7.7 Strategic Collaborations
  • 12.7.8 Recent Developments
• 12.8 NLS Pharmaceutics Ltd.
  • 12.8.1 Overview
  • 12.8.2 Financials
  • 12.8.3 Narcolepsy Treatment Portfolio
  • 12.8.4 Commercial Strategy
  • 12.8.5 Key Products
  • 12.8.6 Market Position
  • 12.8.7 Strategic Collaborations
  • 12.8.8 Recent Developments
• 12.9 Aardvark Therapeutics, Inc.
  • 12.9.1 Overview
  • 12.9.2 Financials
  • 12.9.3 Narcolepsy Treatment Portfolio
  • 12.9.4 Commercial Strategy
  • 12.9.5 Key Products
  • 12.9.6 Market Position
  • 12.9.7 Strategic Collaborations
  • 12.9.8 Recent Developments
• 12.10 Zevra Therapeutics, Inc.
  • 12.10.1 Overview
  • 12.10.2 Financials
  • 12.10.3 Narcolepsy Treatment Portfolio
  • 12.10.4 Commercial Strategy
  • 12.10.5 Key Products
  • 12.10.6 Market Position
  • 12.10.7 Strategic Collaborations
  • 12.10.8 Recent Developments

13. Treatment Gap Analysis

• 13.1 Unmet Clinical Needs
• 13.2 Treatment Limitations Assessment
• 13.3 Access and Affordability Challenges
• 13.4 Innovation Opportunities
• 13.5 Future Treatment Potential

14. Future Outlook and Strategic Recommendations

• 14.1 Emerging Treatment Trends
• 14.2 Orexin-Based Therapy Market Potential
• 14.3 Innovation Roadmap
• 14.4 Strategic Opportunities for Stakeholders
• 14.5 Future Treatment Landscape Outlook

15. Research Methodology

• 15.1 Primary Research
• 15.2 Secondary Research
• 15.3 Treatment Landscape Assessment Framework
• 15.4 Data Validation and Triangulation
• 15.5 Assumptions and Limitations

16. Appendix

• 16.1 Abbreviations
• 16.2 Glossary of Terms
• 16.3 References
• 16.4 List of Tables
• 16.5 List of Figures
• 16.6 Regulatory Sources
• 16.7 Company Sources
• 16.8 Clinical Guidelines Sources
• 16.9 Scientific Literature Sources